2 July 2010 – The U.S. House of Representatives has passed a measure banning patent settlements struck between brand-name and generic pharmaceutical companies to delay the release of generic drugs. The goal? To shave nearly $2 billion off government spending over the next decade. The measure was tacked onto the Iraq and Afghanistan war funding bill.

Please see full article below for more information.